Diabetes, hyperglycemia and evolution of patients with COVID-19

Authors

Keywords:

coronavirus infections, diabetes mellitus, hyperglycemia, risk factors, complications, hypertension, myocardial ischemia, tobacco use disorder, renal insufficiency, chronic.

Abstract

Introduction: Diabetes mellitus and hyperglycemia, in patients with COVID-19, predispose to greater severity of the disease and worse short-term outcomes.
Objective: To identify clinical differences, of humoral parameters, evolution and in the use of medications in patients infected with SARS-CoV-2; in relation to glycemic status, during the COVID-19 pandemic.
Methods: Retrospective study of all patients infected with SARS-CoV-2, treated at the Hospital Militar Dr. Mario Muñoz Monroy _until June/2020. Demographic variables, evolution of symptoms, hospital stay, personal pathological history, humoral parameters on admission, complications and use of medications were collected. Three groups were created: diabetic (n = 16), hyperglycemic (fasting blood glucose ≥ 7.8 mmol/L; n = 10) and normo glycemic (n = 219). Chi-square and Kruskal-Wallis H test were used for comparisons between groups. A 95% confidence interval was used.
Results: Diabetic and hyperglycemic patients had a higher proportion of symptoms on admission, arterial hypertension, ischemic heart disease, chronic renal insufficiency, other antecedents, complications, mortality, and use of steroids and Jusvinza. In addition, they had lower values of hematocrit and lymphocytes, and higher values of neutrophils, platelets, creatinine, aspartate amino transferase, glutamyl transpeptidase, alkaline phosphatase and lactic dehydrogenase.
Conclusions: Both diabetes and hyperglycemia predisposed to more severe clinical forms of COVID-19, with worse humoral parameters, evolution and higher mortality. Steroids and Jusvinza were used more frequently in these patients.

Downloads

Download data is not yet available.

Author Biography

Rubén González Tabares, Hospital Militar de Ejército "Dr. Mario Muñoz Monroy". Matanzas.

Especialista en Endocrinología, médico asistencial, Hospital Clínico Quirúrgico Docente ¨ Dr. Mario Muñoz Monroy¨

References

1. Chung SM, Lee YY, Ha E, Yoon JS, Won KC, Lee HW, et al. The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study. Diabetes & metabolism journal. 2020 [acceso: 1/09/2020]; 44(3):405-13. Disponible en: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087532305&doi=10.4093%2fdmj.2020.0105&partnerID=40&md5=469-4c060d41edb21d47f44f1ec65c05d

2. Rastad H, Karim H, Ejtahed HS, Tajbakhsh R, Noorisepehr M, Babaei M, et al. Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease. Diabetology and Metabolic Syndrome. 2020 [acceso: 1/09/2020]; 12(1):11. Disponible en: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088011066&doi=10.1186%2fs13098-020-00565-9&partnerID=40&md5=8b932cc30dcc834e426208ebc16f8e05

3. Li Y, Han X, Alwalid O, Cui Y, Cao Y, Liu J, et al. Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study. Diabetes Research and Clinical Practice. 2020[acceso: 1/09/2020]; 166:10. Disponible en: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087855134&doi=10.1016%2fj.diabres.2020.108299&partnerID=40&m-d5=075d4fc441c552bc640d80af133f2594

4. Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M, et al. Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study. Diabetes Research and Clinical Practice. 2020[acceso: 1/09/2020]; 165: 8. Disponible en: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085763427&doi=10.1016%2fj.diabres.2020.108227&partnerID=40&m-d5=ae17ce73d1687129b84e48659620a479

5. Bess Constantén S, Alonso Alomá I, Sánchez Sordo E, Martínez Morales MÁ, López Nistal LM, Alonso Expósito I, et al. Anuario Estadístico de Salud 2019. La Habana: Ministerio de Salud Pública Dirección de Registros Médicos y Estadísticas de Salud; 2020. [acceso: 1/09/2020]. Disponible en: http://files.sld.cu/bvscuba/files/2020/05/Anuario-Electr%C3%B3nico-Espa%C3%B1ol-2019-ed-2020.pdf

6. Federación Internacional de la Diabetes. Atlas de la Diabetes de la FID. Bruselas, Bélgica; 2019. [acceso: 1/09/2020]. Disponible en: https://www.diabetesatlas.org/es/resources/

7. American Diabetes Association 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes - 2020. Diabetes Care. 2020 [acceso: 1/09/2020]; 43(Supplement 1):S193-202. Disponible en: https://care.diabetesjournals.org/content/diacare/43/Supplement-_1/S193.full.pdf

8. Zhu L, She Z-G, Cheng X, Qin J-J, Zhang X-J, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020 [acceso: 1/09/2020]; 31(6):1068-77. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252168/pdf/main.pdf

9. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. Journal of Diabetes Science and Technology. 2020 [acceso: 1/09/2020]; 14(4):813-21. Disponible en: https://journals.sagepub.com/doi/abs/10.1177/1932296820924469

10. Liu Z, Liu S, Wang Z, Liu C, Long F, Jin P. Relation between blood glucose and the prognosis of severe coronavirus disease 2019. J Cent South Univ (Med Sci). 2020 [acceso: 1/09/2020]; 45(5):530-5. Disponible en: http://xbyxb.csu.edu.cn/xbwk/fileup/PDF/202005530.pdf

11. Almeida Cruz Y, Reyes Carmona S, Guerra Valdés E A, Alonso Porro I, Alemañy Castilla C, Steyners Patiño D, et al. Covid19 Cuba Data; 2020 [acceso: 1/09/2020]. Disponible en: https://covid19cubadata.github.io/#cuba

12. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro surveillance: bulletin Europeen sur les maladies transmissibles. 2020[acceso: 1/09/2020]; 25(10):5. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078829/

13. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. The New England journal of medicine. 2020[acceso: 1/09/2020]; 382(12):1177-9. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121626/

14. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. The New England journal of medicine. 2020[acceso: 1/09/2020]; 382(10):970-1. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120970/

15. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation. 2016[acceso: 1/09/2020]; 133(24):2459-502. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910510/

16. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020[acceso: 1/09/2020]; 395(10229):1054-62. Disponible en: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081901579&doi=10.1016%2fS0140-6736%2820%2930566-3&partnerID=40&md5=60b48cc828061e7b65a326e43414171d

17. Marhl M, Grubelnik V, Magdič M, Markovič R. Diabetes and metabolic syndrome as risk factors for COVID-19. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020[acceso: 1/09/2020]; 14(4):671-7. Disponible en: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084707663&doi=10.1016%2fj.dsx.2020.05.013&partnerID=40&md5-=d113b7d5293620a6a1ec37c5d8ede7b7

1 8. Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care. 2020[acceso: 1/09/2020]; 43(7):1382-91. Disponible en: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086792869&doi=10.2337%2fdc20-0598&partnerID=40&md5=98144d1b276222d9d667cffb3e501b90

1 9. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care. 2020[acceso: 1/09/2020]; 43(7):1399-407. Disponible en: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086089021&doi=10.2337%2fdc20-0660&partnerID=40&md5=057a60ad986eea195342a5b37716c79b

20. Zhang Y, Li H, Zhang J, Cao Y, Zhao X, Yu N, et al. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan. Diabetes, Obesity and Metabolism. 2020[acceso: 1/09/2020]; 22(8):1443-54. Disponible en: https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.14086

21. Khateeb J, Fuchs E, Khamaisi M. Diabetes and Lung Disease: A Neglected Relationship. The review of diabetic studies : RDS. 2019[acceso: 1/09/2020]; 15:15.. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760893/

22. Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, et al. Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care. 2020[acceso: 1/09/2020]; 43(7):1408-15.. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305003/

Downloads

Published

2021-04-01

How to Cite

1.
González Tabares R, Acosta González FA, Oliva Villa E, Rodríguez Reyes SF, Cabeza Echevarría I. Diabetes, hyperglycemia and evolution of patients with COVID-19. Rev Cubana Med Milit [Internet]. 2021 Apr. 1 [cited 2025 Jan. 8];50(2):e0210960. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/960

Issue

Vol. 50 No. 2 (2021): April - June

Section

Research Article

License

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.